tetano
Editor, Senior Moderator
Microbiol Immunol
. 2020 Jun 24.
doi: 10.1111/1348-0421.12828. Online ahead of print.
Antiviral Activities of Mycophenolic Acid and IMD-0354 Against SARS-CoV-2
Fumihiro Kato[SUP] 1 [/SUP], Shutoku Matsuyama[SUP] 1 [/SUP], Miyuki Kawase[SUP] 1 [/SUP], Takayuki Hishiki[SUP] 2 [/SUP], Hiroshi Katoh[SUP] 1 [/SUP], Makoto Takeda[SUP] 1 [/SUP]
Affiliations
Abstract
In this study, anti-SARS-CoV-2 activity of mycophenolic acid (MPA) and IMD-0354 was analyzed, these compounds were chosen based on their antiviral activities against other coronaviruses. Since they also inhibit Dengue virus (DENV) infection, other anti-DENV compounds/drugs were also assessed. Using SARS-CoV-2-infected VeroE6/TMPRSS2 cells, MPA and IMD-0354, but not other anti-DENV compounds/drugs, showed significant anti-SARS-CoV-2 activity. Although MPA reduced the viral RNA level by only ~100-fold, its EC[SUB]50[/SUB] was as low as 0.87?M, which is easily achievable at therapeutic doses of mycophenolate mofetil. MPA targets coronaviral papain-like protease and its study would be useful in the development of novel anti-SARS-CoV-2 drugs. This article is protected by copyright. All rights reserved.
Keywords: Antiviral agents; IMD-0354; Mycophenolic acid; SARS-CoV-2; VeroE6/TMPRSS2.
. 2020 Jun 24.
doi: 10.1111/1348-0421.12828. Online ahead of print.
Antiviral Activities of Mycophenolic Acid and IMD-0354 Against SARS-CoV-2
Fumihiro Kato[SUP] 1 [/SUP], Shutoku Matsuyama[SUP] 1 [/SUP], Miyuki Kawase[SUP] 1 [/SUP], Takayuki Hishiki[SUP] 2 [/SUP], Hiroshi Katoh[SUP] 1 [/SUP], Makoto Takeda[SUP] 1 [/SUP]
Affiliations
- PMID: 32579258
- DOI: 10.1111/1348-0421.12828
Abstract
In this study, anti-SARS-CoV-2 activity of mycophenolic acid (MPA) and IMD-0354 was analyzed, these compounds were chosen based on their antiviral activities against other coronaviruses. Since they also inhibit Dengue virus (DENV) infection, other anti-DENV compounds/drugs were also assessed. Using SARS-CoV-2-infected VeroE6/TMPRSS2 cells, MPA and IMD-0354, but not other anti-DENV compounds/drugs, showed significant anti-SARS-CoV-2 activity. Although MPA reduced the viral RNA level by only ~100-fold, its EC[SUB]50[/SUB] was as low as 0.87?M, which is easily achievable at therapeutic doses of mycophenolate mofetil. MPA targets coronaviral papain-like protease and its study would be useful in the development of novel anti-SARS-CoV-2 drugs. This article is protected by copyright. All rights reserved.
Keywords: Antiviral agents; IMD-0354; Mycophenolic acid; SARS-CoV-2; VeroE6/TMPRSS2.